A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain

Abstract

The analysis shows that pregabalin is a cost-effective alternative to usual care in patients with refractory NeP, with an ICER well below the threshold typically adopted by UK health technology assessment groups, such as NICE.